Xagenic scores Series B funds
Toronto-based molecular diagnostics company Xagenic has secured C$15 million in Series B funding. The investors included Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation.
10 July 2015•4 mins read
